Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2041 to 2055 of 8933 results

  1. SEEG-guided radiofrequency thermocoagulation in refractory epilepsy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Lumella Pre-Eclampsia Test (MT687)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  3. Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID6549]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Dronabinol for treating muscle spasticity in multiple sclerosis after 2 treatments [TSID10638]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Tirzepatide for treating type 2 diabetes [ID3938]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  6. Heart failure - sacubitril valsartan [ID822]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  7. Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  8. Empagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  9. Ertugliflozin in a triple therapy regimen for treating type 2 diabetes [ID1160]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  10. Ertugliflozin as monotherapy and in dual therapy for treating type 2 diabetes [ID1158]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  11. Dapagliflozin in triple therapy regimens for treating type 2 diabetes [ID962]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  12. Diabetes (type 2) - canagliflozin, dapagliflozin and empagliflozin (monotherapy) [ID756]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  13. Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  14. Canagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  15. Dapagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation